Biotech Leadership Brief | PresightIQ
PresightIQ

Life Sciences Leadership

Market Intelligence Brief

Biotech · C-suite and VP and Board leadershipPeriod: 18 Oct 2026 – 31 Oct 2026Entries: 11

Seats the facts suggest are forming, before any announcement. Our read, with the facts cited.

#CompanyHeadlineSeat in playDecides
01Dren Bio
San Carlos CA
$350M private financing closed to fund late-stage development, filing and planned launch of dibotatug; two investor partners join boardCFO · VP SalesNenad Tomasevic
Chief Executive Officer and Founder, Dren Bio
02Magnet Biomedicine
Boston MA
Senior Vice President and Head of Research Bret Williams leaves for Fathom Therapeutics as CSO; no successor, interim or search stated by MagnetVP ResearchBrian Safina
President & Chief Executive Officer, Magnet Biomedicine
03Etcelera
Somerville MA
Flagship Pioneering merges Cellarity, Etiome and Empress platforms into Etcelera; no leadership beyond CEO and chair namedChief Business OfficerAdrian (Ad) Rawcliffe
Chief Executive Officer, Etcelera; CEO-Partner, Flagship Pioneering
04Star Therapeutics
South San Francisco CA
$200 million private financing for preclinical programs, after Incyte bought subsidiary Vega; no seat statedChief Medical OfficerAdam Rosenthal
Founder, Chief Executive Officer and Board Chair, Star Therapeutics
05Hexagon Bio
Menlo Park CA
$62 million Series C closed to take HEX-360 into the clinic (first-in-human planned H1 2027); no seat statedVP Clinical Operations · VP Regulatory AffairsMaureen Hillenmeyer
Co-founder and Chief Executive Officer, Hexagon Bio
06Sagimet Biosciences
Foster City CA
First patient dosed in US Phase 3 AURORA trial of denifanstat in acne; no commercial or regulatory leader named on the leadership pageChief Commercial Officer · VP Regulatory AffairsDavid Happel
Chief Executive Officer, Sagimet Biosciences
07Voyager Therapeutics
Lexington MA
CEO succession plan: President Robin Swartz expected to succeed CEO Al Sandrock in Q1 2027; no CFO named since May 2026Chief Executive Officer: Filled · CFO · COORobin Swartz
President, Voyager Therapeutics (expected CEO from Q1 2027)
08Rapport Therapeutics
Boston MA
Positive Phase 2 bipolar mania data, then stock and convertible notes offerings closed; leadership page lists no commercial leaderChief Commercial OfficerAbraham N. Ceesay
Chief Executive Officer, Rapport Therapeutics
09TriGemX Bio
New York NY
SPAC merger with TCGX Acquisition Corp. announced with $160M PIPE, about $246M expected gross proceeds; Phase 3 migraine programme; no commercial or regulatory leader on leadership pageChief Commercial Officer · Independent Board Director · General CounselJeff Goater
Chief Executive Officer, TriGemX Bio
01

Dren Bio

San Carlos CA ·

$350M private financing closed to fund late-stage development, filing and planned launch of dibotatug; two investor partners join board

CFOVP Sales

What happened

  • Dren Bio announced the closing of an oversubscribed $350 million private financing, 29 Oct 20261
  • Round co-led by Juvia Group and Lightspeed Venture Partners; new investors include Mirae Asset Capital Life Science, General Catalyst, Cormorant Asset Management and OrbiMed1
  • Proceeds to support continued late-stage clinical development, regulatory submission and planned commercial launch of dibotatug (DR-01), and expansion into additional indications and the broader pipeline1
  • Sujal Shah (Co-Founder and Managing Director, Juvia Group) and Shelley Chu, M.D., Ph.D. (Partner, Lightspeed) appointed to the Board of Directors1
  • Dibotatug: Ph1/2 study in cytotoxic T-cell lymphoma and LGLL with more than 300 patients dosed; no filing date stated1
  • Leadership page lists a CEO, a President and COO, an EVP Finance, an SVP Head of Commercial, an EVP Head of Clinical Development, an SVP Regulatory Affairs and a VP Medical Affairs; it lists no Chief Financial Officer, Chief Medical Officer, Chief Commercial Officer or head of People (checked 31 Oct 2026)2
  • SVP Head of Commercial Benjamin Kozub joined in May 2026 and VP Medical Affairs Johnathan Maher in October 20262
  • The release states a planned commercial launch of dibotatug; it names no commercial partner, no search and no new executive1
  • BioSpace (29 Oct 2026): the Phase 1/2 trial of dibotatug in CTL and LGLL has a primary readout slated for this December, according to ClinicalTrials.gov3
  • BioSpace (29 Oct 2026): Dren lists the haematologic malignancy programme in its online pipeline as in registrational development3

Seat in play

Our read

Dren Bio closed a $350 million round on 29 Oct 2026 to fund the regulatory submission and planned commercial launch of dibotatug, and its leadership page shows finance led by an EVP Finance with no Chief Financial Officer listed, so a launch-stage CFO may be among the next senior hires12. The commercial build has started, with an SVP Head of Commercial who joined in May 2026 and a VP Medical Affairs who joined in October 2026, which suggests field leadership such as a VP Sales may follow as the launch nears2. BioSpace reported on 29 Oct 2026 that the CTL and LGLL trial has a primary readout slated for this December, which may be when filing and launch hiring firms up3.

What could hold it back

  • Shown EVP Finance Jeff Macfarland has been in post since May 2021, so the company could elevate him rather than search for a CFO2.
  • Shown The company has stated no filing date, and the trial readout is still ahead, so launch hiring may wait on the data13.
  • Open Whether a search firm is already engaged, or whether the new lead investors on the board bring candidates from their own networks.

About the decider: Nenad Tomasevic

Nenad Tomasevic co-founded Dren Bio as CEO in May 2019; before that he was VP of Research at Allakos, which he helped co-found. The $350 million round puts the regulatory submission and planned launch of dibotatug on his desk, alongside two new investor directors from Juvia Group and Lightspeed21.

Questions to ask Nenad Tomasevic

  • With the $350 million round funding the regulatory submission and planned launch of dibotatug, which leadership roles do you expect to add first as Dren Bio moves toward being a commercial company1?
  • Having built Dren Bio from research through late-stage development, how are you thinking about the finance function as the company prepares for a launch21?
  • With a Head of Commercial and a VP Medical Affairs now in post, how do you see the commercial team being built out around the trial's readout23?

Who to call

Decides
Nenad Tomasevic

Chief Executive Officer and Founder, Dren Bio

Verified
✓ drenbio.com, 31 Oct 2026
Domain
drenbio.com
Profile
LinkedIn not found

Co-founded Dren Bio as CEO in May 2019; previously VP of Research at Allakos, which he helped co-found2

Influences
Sujal Shah

Co-Founder and Managing Director, Juvia Group; new Dren Bio board member

Verified
✓ drenbio.com, 29 Oct 2026
Domain
juvia.group
Profile
LinkedIn

Career, from LinkedIn

  1. Co-Founder & Managing Director, Juvia Group
  2. Member of the Board of Directors, Soufflé Therapeutics
  3. Chair of the Board of Directors, Tvardi Therapeutics
  4. Member of the Board of Directors, Opthea
  5. President and CEO, CymaBay Therapeutics
  6. Chief Financial Officer, CymaBay Therapeutics
  7. Consultant / Acting Chief Financial Officer, CymaBay Therapeutics

Carnegie Mellon University - Tepper School of Business, MBA, Accounting and Finance; Northwestern University, MS, Biomedical Engineering; Northwestern University, BS, Biomedical Engineering

Company details

CompanyDren Bio1
OwnershipPrivate, venture-backed1
InvestorsJuvia Group, Lightspeed Venture Partners (co-leads); 8VC, SR One, Taiho Ventures, Mission BioCapital, HBM Healthcare Investments, BVF Partners, Aisling Capital, ArrowMark Partners, Mirae Asset Capital Life Science, General Catalyst, Cormorant Asset Management, OrbiMed1
TypeClinical-stage biotech; lead programme dibotatug in late-stage development (Ph1/2 data in CTL and LGLL)1
Size50 employees (newswire company details, 29 Oct 2026)4
Latest financing$350 million private financing, closed and announced 29 Oct 2026, co-led by Juvia Group and Lightspeed Venture Partners1
AddressSan Carlos, Calif. (release dateline); newswire details list Foster City, CA4
Websitedrenbio.com5

Timeline

  1. Closes $350M private financing; Sujal Shah and Shelley Chu join board1
  2. Johnathan Maher joins as VP of Medical Affairs2
  3. Benjamin Kozub joins as SVP, Head of Commercial (from CymaBay)2
  4. Expanded Sanofi collaboration on a B-cell depleting therapy: $100 million upfront, up to $1.7 billion in milestones; option to co-fund for US co-promotion rights6
  5. Shalini Gidwani joins as SVP of Regulatory Affairs2
  6. Sanofi acquires DR-0201 (now SAR448501)4

Sources

  1. drenbio.com news, 29 Oct 2026
  2. drenbio.com team page, checked 31 Oct 2026
  3. biospace.com, 29 Oct 2026
  4. businesswire.com, 29 Oct 2026
  5. drenbio.com, checked 31 Oct 2026
  6. drenbio.com, 15 Dec 2025
02

Magnet Biomedicine

Boston MA ·

Senior Vice President and Head of Research Bret Williams leaves for Fathom Therapeutics as CSO; no successor, interim or search stated by Magnet

VP Research

What happened

  • Fathom Therapeutics announced on 29 Oct 2026 that Bret Williams, Ph.D., is its new Chief Scientific Officer; he joins from Magnet Biomedicine, where he most recently served as senior vice president and head of research1
  • The release gives no start date at Fathom and does not say when he left Magnet1
  • Magnet's own site (checked 31 Oct 2026) lists no Head of Research, SVP Research or VP Biology; its leadership list shows President & CEO, CMO, CBO and VPs of Drug Discovery, Operations, Portfolio & Program Management, Clinical Operations and Regulatory Affairs. It states no vacancy, interim or search2
  • On 14 Oct 2026 Magnet said Lilly had exercised its right to designate up to two additional collaboration projects, bringing the total to three active molecular glue programmes3
  • Magnet signed a collaboration and license agreement with Eli Lilly on 28 Feb 2025, to receive up to $40 million in upfront, near-term payments and an equity investment4
  • CEO Brian Safina said the Lilly deal helps fund work toward the clinic and that Magnet could raise more as programmes approach it; no timeline given5

Seat in play

Our read

Magnet's senior vice president and head of research, Bret Williams, has left to become Chief Scientific Officer at Fathom Therapeutics (announced 29 Oct 2026), and Magnet's leadership page, checked 31 Oct 2026, lists no research head and names no successor or interim12. On 14 Oct 2026 Magnet said Lilly had designated up to two more projects, bringing it to three active molecular glue programmes with Lilly, alongside its own ST2 and TL1A programmes at lead optimisation, so senior research leadership may be among its next hires32. The CEO has said the Lilly deal helps fund work to take programmes into the clinic, with a further raise possible as they approach it, a stage that often calls for a research leader able to hand candidates to development5.

What could hold it back

  • Shown Matthew Hayward, VP of Drug Discovery, is in post and could cover the research work2.
  • Open Whether Magnet has begun a search, named an interim, or will take a candidate from ARCH or Newpath's network.

About the decider: Brian Safina

Brian Safina is President & CEO of Magnet; before Magnet he was at Bolt Biotherapeutics and spent 2004 to 2018 at Genentech. The departure of the head of research may put the shape of research leadership on his desk while the Lilly collaboration grows to three programmes2613.

Questions to ask Brian Safina

  • How are you thinking about research leadership now that the Lilly collaboration has grown to three active programmes3?
  • As ST2 and TL1A move toward the clinic, which senior capabilities do you expect the team to need next25?
  • How do ARCH and Newpath usually take part when Magnet adds senior leaders7?

Who to call

Decides
Brian Safina

President & Chief Executive Officer, Magnet Biomedicine

Verified
✓ magnetbiomedicine.com, 31 Oct 2026
Domain
magnetbiomedicine.com
Profile
LinkedIn

Career, from LinkedIn

  1. President & CEO , Magnet Biomedicine
  2. President and Chief Scientific Officer, Magnet Biomedicine
  3. Senior Vice President, Discovery Research, Bolt Biotherapeutics, Inc.
  4. Vice President, Protein & Medicinal Chemistry, Bolt Biotherapeutics, Inc.
  5. Vice President, Chemistry, Bolt Biotherapeutics, Inc.

The Scripps Research Institute, Organic Chemistry; University of California, San Diego, PhD, Synthetic Organic Chemistry; Loyola Marymount University, Bachelor's degree, Chemistry

Company details

CompanyMagnet Biomedicine2
InvestorsARCH Venture Partners and Eli Lilly and Company shown under "Our Investors" on the company site2
TypePlatform company (TrueGlue molecular glue platform); lead programmes (ST2, TL1A) shown at lead optimisation2
Latest financing$50 million Series A, 19 Sep 2023, co-led by Newpath Partners and ARCH Venture Partners7
Address321 Harrison Ave Suite 600, Boston, MA 021182
Websitemagnetbiomedicine.com2

Timeline

  1. Fathom Therapeutics names Bret Williams, from Magnet, as Chief Scientific Officer1
  2. Magnet launches with $50 million Series A co-led by Newpath Partners and ARCH; Williams then listed as Vice President of Biology7

Sources

  1. prnewswire.com, 29 Oct 2026
  2. magnetbiomedicine.com, checked 31 Oct 2026
  3. linkedin.com (Magnet Biomedicine company post), 14 Oct 2026
  4. prnewswire.com, 28 Feb 2025
  5. endpoints.news, 28 Feb 2025
  6. linkedin.com, profile checked 31 Oct 2026
  7. prnewswire.com, 19 Sep 2023
03

Etcelera

Somerville MA ·

Flagship Pioneering merges Cellarity, Etiome and Empress platforms into Etcelera; no leadership beyond CEO and chair named

Chief Business Officer

What happened

  • Flagship Pioneering announced the formation of Etcelera on 29 Oct 2026, created by the merger of the platforms of Cellarity, Etiome and Empress Therapeutics1
  • Ad Rawcliffe, CEO-Partner at Flagship Pioneering, leads Etcelera as CEO; the release names no other executives2
  • Alec Reynolds, Senior Partner at Flagship Pioneering, is Chairman of Etcelera2
  • No new funding was announced with the launch; the three predecessor companies had raised $374 million in venture capital before the merger3
  • CEO says the next six to 12 months will bring substantial business development activity with partners4
  • An oral sickle cell disease drug that Cellarity discovered moves into a separate standalone company, not Etcelera3
  • Etcelera keeps the 2022 Novo partnership with Cellarity in MASH; a second large-pharma alliance is in the works, per the CEO3
  • Company site shows a single line about the three companies and no leadership page (checked 31 Oct 2026)5
  • CEO Ad Rawcliffe describes Etcelera's future as quite partnership oriented4
  • The release states the company's goal includes high-impact partnerships and data services alongside more and better medicines1
  • Rawcliffe said the $374 million the three predecessors raised will help carry the company further3

Seat in play

  • Chief Business Officer431

Our read

Flagship formed Etcelera on 29 Oct 2026 from the platforms of Cellarity, Etiome and Empress Therapeutics, and the launch names only the CEO and the chair12. The CEO calls the company's future quite partnership oriented and says the next six to 12 months will bring substantial business development activity, with the Novo MASH partnership retained and a second large-pharma alliance in the works, so senior deal leadership may be among the first seats the combined company fills43.

What could hold it back

  • Open Whether business development leaders from Cellarity, Etiome or Empress carry over into Etcelera; no page names them.
  • Open Whether Flagship, which supplies the CEO and chair, places someone from its own network or runs the hire through its own talent team.
  • Shown No new funding was announced with the launch; the CEO says the $374 million the three companies raised will help carry the company further, so the pace of senior hiring may depend on existing capital3.

About the decider: Adrian (Ad) Rawcliffe

Ad Rawcliffe has been CEO of Etcelera since its formation on 29 Oct 2026 and CEO-Partner at Flagship since Jan 2026, when he also became CEO of Etiome; before that he was CEO of Adaptimmune (Aug 2019 to Jan 2026), its CFO from Mar 2015, and earlier SVP Worldwide Business Development at GlaxoSmithKline. The merger puts the combination of three platforms and a planned run of partnering deals over the next six to 12 months on his desk2647.

Questions to ask Adrian (Ad) Rawcliffe

  • Having led worldwide business development at GlaxoSmithKline, how are you thinking about the team that will carry the partnering activity you expect over the next six to 12 months47?
  • Now that the Cellarity, Etiome and Empress platforms sit in one company, which leadership roles do you see the combined company needing first1?
  • With partnerships and data services alongside your own hematology, metabolism and immunology programmes, how do you see the balance between partnering and advancing programmes in-house14?

Who to call

Decides
Adrian (Ad) Rawcliffe

Chief Executive Officer, Etcelera; CEO-Partner, Flagship Pioneering

Verified
✓ prnewswire.com, 29 Oct 2026
Domain
flagshippioneering.com
Profile
LinkedIn

Joined Flagship in Jan 2026 as CEO-Partner and CEO of Etiome; previously CEO of Adaptimmune Therapeutics6

Influences
Alec Reynolds

Chairman, Etcelera; Senior Partner, Flagship Pioneering

Verified
✓ prnewswire.com, 29 Oct 2026
Domain
flagshippioneering.com
Profile
LinkedIn

Previously interim President of Cellarity and COO of Flagship's Pioneering Medicines unit8

Career, from LinkedIn

  1. Chief Executive Officer, Expedition Medicines
  2. Senior Partner, Flagship Pioneering
  3. Executive Chair, Cellarity
  4. COO, Pioneering Medicines, Flagship Pioneering
  5. President, Cellarity
  6. Corporate Vice President, Celgene
  7. Vice President, Celgene

Princeton University, AB, Politics; University of Virginia Darden School of Business, Master of Business Administration (MBA)

Company details

CompanyEtcelera2
OwnershipA Flagship Pioneering company, launched with continued support from Flagship Pioneering and others2
InvestorsFlagship Pioneering and others (not named)2
TypePlatform company; programs in hematology (myelofibrosis, essential thrombocythemia, preclinical), metabolism (partnered MASH) and immunology4
Latest financingNone announced with launch3
Total raisedPredecessor companies raised $374 million in venture capital before the merger (per BioPharma Dive)3
AddressSomerville, Mass. (street address not found)2
Websiteetcelera.com5

Timeline

  1. Flagship forms Etcelera from Cellarity, Etiome and Empress platforms; Rawcliffe CEO, Reynolds Chairman1
  2. Adrian Rawcliffe joins Flagship as CEO-Partner and CEO of Etiome6
  3. Cellarity starts Phase 1 study of CLY-124 in sickle cell disease4

Sources

  1. flagshippioneering.com, 29 Oct 2026
  2. prnewswire.com, 29 Oct 2026
  3. biopharmadive.com, 29 Oct 2026
  4. fiercebiotech.com, 29 Oct 2026
  5. etcelera.com, checked 31 Oct 2026
  6. flagshippioneering.com, 8 Jan 2026
  7. linkedin.com, checked 31 Oct 2026
  8. flagshippioneering.com, checked 31 Oct 2026
04

Star Therapeutics

South San Francisco CA ·

$200 million private financing for preclinical programs, after Incyte bought subsidiary Vega; no seat stated

Chief Medical Officer

What happened

  • Star Therapeutics announced a $200 million private financing on 23 Oct 2026, co-led by OrbiMed and Janus Henderson Investors1
  • Proceeds are to advance its current preclinical programs into the clinic and expand the pipeline with additional programs1
  • The financing follows Incyte's July 2026 completed acquisition of Star subsidiary Vega Therapeutics, including lead programme latarcibart (VGA039), in a transaction valued at up to $2 billion1
  • Janus Henderson's Vish Sridharan is joining as a board observer for Star1
  • Leadership page lists four managers: CEO/Founder/Board Chair, CSO, CBO and CFO (one person), and SVP Head of HR; it lists no chief medical, clinical development, regulatory, CMC/technical or commercial leader (checked 31 Oct 2026)2
  • Star’s lead program latarcibart (VGA039), in Phase 3 development, was included in the Vega Therapeutics sale to Incyte; the release describes Star’s current programs as preclinical1
  • Star's 21 Apr 2026 release quoted Gary Patou, M.D., as Chief Medical Officer of Star Therapeutics, while the VGA039 pivotal Phase 3 was enrolling3

Seat in play

  • Chief Medical Officer123

Our read

Star has raised $200 million to take its preclinical programmes into the clinic, but the clinical-stage drug it had in Phase 3 went to Incyte with Vega Therapeutics in July 2026, so the company may be rebuilding its clinical side from a preclinical start1. Star named Gary Patou as its Chief Medical Officer, yet the leadership page checked on 31 Oct 2026 lists no medical or clinical leader32. That suggests a medical leader for the new programmes may be among the first senior hires this round funds, with the timing likely tied to when the first programme nears the clinic, which no page states12.

What could hold it back

  • Open When the first preclinical programme is expected to enter the clinic: the release gives no date, so the hire could wait until a programme is close.
  • Open Whether a medical leader has already been engaged, as an employee, adviser or consultant, without appearing on the leadership page, or whether a search is already under way.
  • Open Whether the lead investors place a candidate from their own networks.

About the decider: Adam Rosenthal

Adam Rosenthal founded Star in 2018 and has been CEO since inception; he is also Board Chair, and earlier was Chief Business Officer at True North Therapeutics and co-founder and CEO of Electra Therapeutics, and his profile lists him as CEO and co-founder of Vega Therapeutics (2018–2026). After Incyte's acquisition of Vega, he now has $200 million to take Star's preclinical programmes into the clinic and add new ones241.

Questions to ask Adam Rosenthal

  • Having taken VGA039 from the Star platform into a pivotal Phase 3 before the Vega sale, how are you thinking about the medical and clinical leadership for the next programmes as they approach the clinic13?
  • Which of the current preclinical programmes do you expect to lead into the clinic first, and what will the team need around it at that point1?
  • With OrbiMed and Janus Henderson co-leading the round, how do you and the board expect to approach the senior hires for this next phase1?

Who to call

Decides
Adam Rosenthal

Founder, Chief Executive Officer and Board Chair, Star Therapeutics

Verified
✓ star-therapeutics.com, 31 Oct 2026
Domain
star-therapeutics.com
Profile
LinkedIn

Founded Star in 2018 and has been CEO since inception; earlier Chief Business Officer at True North Therapeutics and co-founder and CEO of Electra Therapeutics2

Career, from LinkedIn

  1. CEO and Founder, Star Therapeutics
  2. CEO and Co-Founder, Vega Therapeutics
  3. CEO and Co-Founder, Electra Therapeutics
  4. Chief Business Officer, True North Therapeutics
  5. VP, Head of Corporate Development, iPierian

Massachusetts Institute of Technology / Harvard Medical School, PhD, Biomedical Engineering; Massachusetts Institute of Technology, MEng, Electrical Engineering & Computer Science; Massachusetts Institute of Technology, BS, Electrical Engineering; Brain and Cognitive Science

Runs the process
Monica Kamio

SVP, Head of Human Resources, Star Therapeutics

Verified
✓ star-therapeutics.com, 31 Oct 2026
Domain
star-therapeutics.com
Profile
LinkedIn not found

Oversees HR strategy and operations including recruitment; earlier VP of Human Resources at Arch Capital Services2

Influences
Carl Gordon

Managing Partner, OrbiMed (co-lead investor)

Verified
✓ star-therapeutics.com, 23 Oct 2026
Domain
orbimed.com
Profile
LinkedIn

Career, from LinkedIn

  1. Managing Partner , OrbiMed Advisors
  2. Founding General Partner, OrbiMed Advisors
  3. Biotechnology Analyst , Mehta and Isaly
  4. Postdoctoral Fellow, The Rockefeller University
  5. Computational Biology, Imclone Systems

Massachusetts Institute of Technology, Ph.D., Department of Biology ; Harvard University, Bachelor's degree, Chemistry & Physics ; Munster High School

Company details

CompanyStar Therapeutics1
OwnershipPrivate (announced a private financing)1
InvestorsCo-led by OrbiMed and Janus Henderson Investors, with Agent Capital, Catalio Capital Management, Cormorant Asset Management, New Leaf Venture Partners, NYBC Ventures, RA Capital Management, Redmile, Sofinnova Investments, Soleus Capital and a leading sovereign wealth fund1
TypeBiotechnology company; current programmes preclinical1
Latest financing$200 million private financing, 23 Oct 2026, co-led by OrbiMed and Janus Henderson Investors1
Address201 Haskins Way, 5th Floor, South San Francisco, CA 940802
Main phone888-742-13382
Websitestar-therapeutics.com

Timeline

  1. Announces $200 million private financing co-led by OrbiMed and Janus Henderson Investors1
  2. Spinout Electra Therapeutics becomes publicly traded (Nasdaq: ETRA)1
  3. Incyte completes acquisition of Vega Therapeutics, Star's wholly owned subsidiary5
  4. Incyte agrees to acquire Vega Therapeutics for $1.25 billion, with up to $750 million more on sales milestones5
  5. Presents early VGA039 data at ASH; Phase 3 dosing under way5
  6. Raises $125 million Series D, co-led by Sanofi Ventures and Viking Global Investors5

Sources

  1. star-therapeutics.com, 23 Oct 2026
  2. star-therapeutics.com, checked 31 Oct 2026
  3. star-therapeutics.com, 21 Apr 2026
  4. linkedin.com, checked 31 Oct 2026
  5. star-therapeutics.com, checked 31 Oct 2026
05

Hexagon Bio

Menlo Park CA ·

$62 million Series C closed to take HEX-360 into the clinic (first-in-human planned H1 2027); no seat stated

VP Clinical OperationsVP Regulatory Affairs

What happened

  • Hexagon Bio announced the closing of a $62 million Series C financing on 23 Oct 2026, led by The Column Group, with existing investors Nextech Invest, Deviation Capital, 8VC and CPP Investments participating1
  • The company says proceeds will support the Phase 1 trial of HEX-360 (expected to begin in the first half of 2027) and advance additional novel payload mechanisms and dual payloads from its ADC platform1
  • HEX-360 is currently in IND-enabling studies; the CEO says the capital lets the company transition into a clinical-stage company1
  • The release names no new executive, board member or search; it quotes CEO Maureen Hillenmeyer and Board Chairman Scott Garland1
  • The company's leadership page lists a CEO, Chief Scientific Officer, Chief Medical Officer (Bill Grossman), SVP Drug Discovery, SVP Business Development and two VPs (Biology; Synthetic Biology); it lists no CFO, no regulatory, clinical operations, CMC or people leader (checked 31 Oct 2026)2
  • Bill Grossman's own enGene page says he took the interim Chief Medical Officer role there in June 2026 while staying on enGene's board; Hexagon's page still lists him as Chief Medical Officer and states no change3
  • A Clinical Advisory Board of breast cancer experts was formed in June 2026 to support HEX-360 development4
  • A Hexagon Bio job posting dated 4 Sep 2026 seeks a Sr./Ex. Director or VP, Clinical Scientist, reporting to the Head of Clinical/CMO, to support clinical trial design and regulatory submissions including INDs5

Seat in play

  • VP Clinical Operations125
  • VP Regulatory Affairs12

Our read

Hexagon Bio closed a $62 million Series C on 23 Oct 2026 to fund the Phase 1 trial of HEX-360, now in IND-enabling studies and planned to begin in the first half of 2027, and its CEO says the money lets it transition into a clinical-stage company1. Its leadership page is built around discovery and business development, with a Chief Medical Officer but no clinical operations or regulatory leader, and a September 2026 posting for a clinical scientist reporting to the Head of Clinical/CMO suggests the clinical team is being built now, so the leaders who run a first IND and first trial may be among the next senior hires25.

What could hold it back

  • Shown A Chief Medical Officer, Bill Grossman, is listed on the leadership page and could carry clinical and regulatory leadership himself; his own enGene page says he also took an interim CMO role there in June 202623.
  • Open Whether The Column Group's talent team is already recruiting for these seats, or whether a CRO will run the Phase 1 with a lean in-house team.
  • Open Whether clinical operations or regulatory leads have already been hired below the level the leadership page shows.

About the decider: Maureen Hillenmeyer

Maureen Hillenmeyer co-founded Hexagon Bio and has been its CEO, coming from Stanford, where she directed the Genomes to Natural Products program. The Series C now puts on her desk the move from a discovery platform to a clinical-stage company, with HEX-360's Phase 1 planned for the first half of 202712.

Questions to ask Maureen Hillenmeyer

  • You have said the Series C lets Hexagon move quickly into being a clinical-stage company; how are you thinking about the leadership the HEX-360 Phase 1 will need around the start planned for the first half of 20271?
  • As the clinical team forms under the Chief Medical Officer, which parts of clinical operations and regulatory work do you expect to build in-house, and which to run with partners25?
  • With the round also funding further payload mechanisms and dual payloads, how do you see the balance of the leadership team shifting between the platform and development over the next year or two1?

Who to call

Decides
Maureen Hillenmeyer

Co-founder and Chief Executive Officer, Hexagon Bio

Verified
✓ hexagonbio.com, 23 Oct 2026
Domain
hexagonbio.com
Profile
LinkedIn

Co-founder and CEO; previously director of the Genomes to Natural Products program at the Stanford Technology Genome Center2

Career, from LinkedIn

  1. Founder and CEO, Hexagon Bio
  2. Director of Genomes to Natural Products Program, Stanford University School of Medicine
  3. Group leader, Stanford University School of Medicine

Stanford University School of Medicine, Postdoctoral scholar, Biochemistry; Stanford University, PhD, Biomedical informatics; University of Notre Dame, BS, Biological Sciences

Runs the process
Carla Daniel

Partner & Chief People Officer, The Column Group (lead investor)

Verified
✓ thecolumngroup.com, 31 Oct 2026
Domain
thecolumngroup.com
Profile
LinkedIn

Joined The Column Group in 2015 and assists portfolio companies in recruiting their scientific teams; earlier in HR at Tularik, then roles at Genentech and an executive search firm6

Career, from LinkedIn

  1. Partner & Chief People Officer, The Column Group
  2. Board Member, CxT Discovery
  3. Vice President & Head of Talent, The Column Group
  4. Director of Recruiting, The Column Group
  5. Consultant, Independent
  6. Sourcing Consultant, Genentech

University of California, Santa Cruz, Bachelor of Arts (BA), Anthropology; University of California, Santa Cruz, Master of Arts (MA), Molecular, Cellular and Developmental Biology

Influences
Leon Chen

Partner, The Column Group; listed on Hexagon Bio's board page

Verified
✓ hexagonbio.com, 31 Oct 2026
Domain
thecolumngroup.com
Profile
LinkedIn

Joined The Column Group in 2019; previously Venture Partner at OrbiMed, where he took interim management roles at E-Scape Bio, TranscripTx and Adicet6

Career, from LinkedIn

  1. Partner, The Column Group
  2. Venture Partner, OrbiMed
  3. Partner, Skyline Ventures
  4. Entrepreneur in Residence, Venrock Associates
  5. Founder, KAI Pharmaceuticals

Stanford University Graduate School of Business, MBA, Business; Stanford University School of Medicine, PhD, Pharmacology; Stanford University, Ph.D, Molecular Pharmacology

Company details

CompanyHexagon Bio1
OwnershipPrivate, venture-backed1
InvestorsThe Column Group (lead), Nextech Invest, Deviation Capital, 8VC, CPP Investments1
TypePreclinical biotech; lead programme HEX-360 (HER2-targeting ADC) in IND-enabling studies, Phase 1 planned H1 20271
Latest financingSeries C, $62 million, closing announced 23 Oct 2026, led by The Column Group1
Address1490 O’Brien Drive, Suite E, Menlo Park, CA 940251
Websitehexagonbio.com7

Timeline

  1. Closes $62 million Series C led by The Column Group1
  2. Forms a Clinical Advisory Board of breast cancer experts for HEX-3604
  3. Forms a multi-million dollar joint venture with Corteva4
  4. Appoints Yujiro Hata to the board of directors4

Sources

  1. hexagonbio.com, 23 Oct 2026
  2. hexagonbio.com, checked 31 Oct 2026
  3. engene.com, checked 31 Oct 2026
  4. hexagonbio.com, checked 31 Oct 2026
  5. job-boards.greenhouse.io, 4 Sep 2026
  6. thecolumngroup.com, checked 31 Oct 2026
  7. hexagonbio.com, checked 31 Oct 2026
06

Sagimet Biosciences (SGMT)

Foster City CA ·

First patient dosed in US Phase 3 AURORA trial of denifanstat in acne; no commercial or regulatory leader named on the leadership page

Chief Commercial OfficerVP Regulatory Affairs

What happened

  • First patient dosed in AURORA, Sagimet's pivotal US Phase 3 trial of denifanstat in moderate to severe acne, 22 Oct 2026; intended to support a potential US NDA1
  • Trial to enroll about 800 US patients, 450 of them adolescents; topline results expected in the second half of 20271
  • Sagimet develops denifanstat outside China; license partner Ascletis holds the exclusive China licence1
  • Sagimet closed an underwritten offering of about $115.0 million gross on 1 Oct 2026, led by Commodore Capital; proceeds to fund the Phase 3 trial, pre-launch activities for denifanstat and other programmes2
  • Sagimet intends to use the net proceeds of the Oct 2026 offering, with existing cash, to fund the Phase 3 trial of denifanstat in acne, pre-launch activities for denifanstat, TVB-3567 through Phase 2 topline results and its topical FASN inhibitor programme to IND2
  • Leadership page lists a Senior Vice President of New Products (Robert D'Urso, joined Sep 2024, formerly US Country Manager at ISDIN) and no Chief Commercial Officer, regulatory leader or head of manufacturing/CMC (checked 31 Oct 2026)3
  • Chief Medical Officer Andreas Grauer joined in April 20263

Seat in play

  • Chief Commercial Officer123
  • VP Regulatory Affairs13

Our read

Sagimet dosed the first patient in AURORA, its pivotal US Phase 3 trial of denifanstat in acne, on 22 Oct 2026, with topline results expected in the second half of 2027 and the trial intended to support a potential US NDA1. Sagimet develops denifanstat outside China, and it raised about $115.0 million on 1 Oct 2026 partly to fund pre-launch activities for denifanstat, while its leadership page names no Chief Commercial Officer or regulatory leader123. That suggests commercial and regulatory leadership may be among the next senior hires as the company moves towards the 2027 readout and a potential filing after it12.

What could hold it back

  • Shown A Senior Vice President of New Products, Robert D'Urso, in post since Sep 2024 and formerly US Country Manager at ISDIN, could lead the commercial build3.
  • Shown Topline results are not expected until the second half of 2027, so commercial hiring may wait for the data1.
  • Open Whether Sagimet will launch in the US itself or seek a partner, and whether a commercial search is already under way.

About the decider: David Happel

David Happel has been CEO of Sagimet since Oct 2022, coming from the CEO roles at Cognoa and Chrono Therapeutics, with earlier commercial positions at Raptor Pharmaceuticals and Horizon. The AURORA start and the Oct 2026 financing for pre-launch work may put the shape of the company's first launch team on his desk32.

Questions to ask David Happel

  • How are you thinking about the commercial organisation denifanstat would need, and when it should start to take shape relative to the 2027 readout1?
  • The October financing is earmarked partly for pre-launch activities; which capabilities does the team see as the first priorities for that work2?
  • As AURORA heads towards a potential NDA, how do you see regulatory leadership developing alongside the clinical team1?

Who to call

Decides
David Happel

Chief Executive Officer, Sagimet Biosciences

Verified
✓ sagimet.com, 31 Oct 2026
Domain
sagimet.com
Profile
LinkedIn

Joined as CEO in Oct 2022; previously President and CEO of Cognoa and CEO of Chrono Therapeutics; earlier roles at Horizon Therapeutics, Raptor Pharmaceuticals, Dynavax and Chiron3

Career, from LinkedIn

  1. President & CEO, Sagimet Biosciences
  2. President & CEO, Cognoa
  3. CEO, Chrono Therapeutics
  4. EVP, Global Orphan Business Unit, Horizon Pharma plc
  5. Chief Commercial Officer, Raptor Pharmaceuticals

Indiana State University, MBA, Marketing; Indiana University Bloomington, BA, Chemistry

Runs the process
Elizabeth Rozek

Chief Legal & Administrative Officer, Sagimet Biosciences (oversees HR)

Verified
✓ sagimet.com, 31 Oct 2026
Domain
sagimet.com
Profile
LinkedIn not found

General Counsel & Chief Compliance Officer from April 2023 to October 2025, then Chief Legal & Administrative Officer; previously General Counsel at Cognoa and Basilea3

Company details

CompanySagimet Biosciences Inc.1
OwnershipPublic (Nasdaq: SGMT)1
InvestorsOct 2026 offering led by Commodore Capital, with RA Capital Management, Spruce Street Capital, BVF Partners, Aberdeen Investments, Columbia Threadneedle Investments, Affinity Asset Advisors and Woodline Partners2
TypeClinical-stage biotech (lead programme denifanstat in Phase 3, acne)1
Latest financingUnderwritten offering of Series A common stock and pre-funded warrants, about $115.0 million gross, closed 1 Oct 2026 (8,750,010 shares at $10.00; pre-funded warrants for 2,750,010 shares)2
Cash and runwayCash, cash equivalents and marketable securities of $257.6 million at 30 Jun 2026 (before the Oct 2026 offering); company states current operations funded through 202845
Address950 Tower Lane, Suite 1500, Foster City, CA 944046
Main phone+1 650.561.86006
Websitesagimet.com

Timeline

  1. First patient dosed in AURORA Phase 3 US trial of denifanstat in acne1
  2. Closed about $115.0 million underwritten offering led by Commodore Capital2
  3. Completed underwritten offering of 29,166,700 shares at $6.00, about $175.0 million gross4
  4. Andreas Grauer joined as Chief Medical Officer, most recently CMO at Omeros3
  5. Marie O'Farrell became Chief Scientific Officer (previously SVP R&D); Elizabeth Rozek became Chief Legal & Administrative Officer3

Sources

  1. globenewswire.com, 22 Oct 2026
  2. sagimetbiosciences.gcs-web.com, 1 Oct 2026
  3. sagimet.com, checked 31 Oct 2026
  4. sec.gov, 10-Q for quarter ended 30 Jun 2026
  5. sec.gov, 8-K 11 Aug 2026
  6. sagimet.com, checked 31 Oct 2026
07

Voyager Therapeutics (VYGR)

Lexington MA ·

CEO succession plan: President Robin Swartz expected to succeed CEO Al Sandrock in Q1 2027; no CFO named since May 2026

Chief Executive Officer: filledCFOCOO

What happened

  • Board appointed Robin Swartz, Chief Business Officer and Chief Operating Officer, as President effective 20 Oct 2026; she is expected to succeed CEO Alfred Sandrock in Q1 2027, after initial acute safety data from the VY1706 trial12
  • Sandrock is expected to remain CEO through initial acute safety data with VY1706 (Q1 2027, pending enrollment) and then stay on the Board32
  • Chairman Michael Higgins said the Board unanimously selected Swartz; no search or search firm is mentioned in the release2
  • Swartz has led multiple functions at Voyager, including clinical development, finance, legal and HR2
  • Swartz has also been principal financial officer and treasurer since May 2026; the former CFO resigned effective 8 May 2026 and no new CFO is named45
  • Amy Quinlan, Vice President of Finance since January 2025, was appointed principal accounting officer on 20 Apr 2026, effective 8 May 20265
  • Leadership page lists its management team (CEO, President, Chief Scientific Officer, Chief Corporate Affairs Officer and Chief of Staff); it lists no CFO, COO, CBO, medical, regulatory or people leader (checked 31 Oct 2026)4

Seat in play

  • Chief Executive Officer: Filled (Robin Swartz named President and expected successor in Q1 2027; Sandrock remains CEO until then)1
  • CFO514
  • COO12

Our read

Robin Swartz, Chief Business Officer and Chief Operating Officer and also principal financial officer and treasurer since the CFO left in May 2026, is expected to become CEO in Q1 2027 after initial acute safety data from VY1706, so the operating and finance seats she has carried may need holders around that handover15. The leadership page lists no CFO, and the Nasdaq-listed company reported $149 million in cash at the end of Q2 2026 with runway into 2028, so a dedicated finance leader may be among the first seats the incoming CEO looks at43.

What could hold it back

  • Shown VP Finance Amy Quinlan has been principal accounting officer since May 2026 and could take on more of the finance role5.
  • Shown The handover is tied to initial VY1706 safety data expected in Q1 2027 pending enrollment, so the timing could move, and Swartz has run finance without a CFO since May 2026, so the seats could stay absorbed24.
  • Open Whether a CFO or COO search is already under way, or a firm engaged.

About the decider: Robin Swartz

Robin Swartz was appointed President on 20 Oct 2026 and is expected to succeed Al Sandrock as CEO in Q1 2027; she joined Voyager in January 2021 and has been COO since February 2022, COO and CBO since November 2024, and principal financial officer and treasurer since May 2026. Before Voyager she spent 26 years at Genzyme and Sanofi Genzyme, including over ten years in finance, and the move may put her own former seats and the vacant CFO role on her desk14.

Questions to ask Robin Swartz

  • Having spent over ten years in finance at Sanofi Genzyme and served as Voyager's principal financial officer since May, how are you thinking about finance leadership as you move into the CEO role in Q1 20271?
  • With programmes advancing both in-house and with partners such as Alexion, Novartis and Neurocrine, how do you see the business and operating responsibilities you hold today being organised once you step up2?
  • As VY1706 approaches its initial acute safety data, what will the leadership team need for the next stage of development2?

Who to call

Decides
Robin Swartz

President, Voyager Therapeutics (expected CEO from Q1 2027)

Verified
✓ voyagertherapeutics.com, 31 Oct 2026
Domain
voyagertherapeutics.com
Profile
LinkedIn

Spent 26 years at Genzyme Corporation and Sanofi Genzyme before joining Voyager4

Career, from LinkedIn

  1. Chief Operating Officer, Voyager Therapeutics, Inc.
  2. SVP Portfolio Management and Patient Engagement, Voyager Therapeutics, Inc.
  3. SVP, Head of Patient and Product Services, Sanofi Genzyme
  4. VP, Global and US Business Operations, Sanofi Genzyme
  5. Chief Of Staff, Office of the President , Sanofi Genzyme

Kenyon College, Bachelor's degree, Political Science and Government; IMD Business School, Executive Program; American University, Conflict Resolution and Policy

Decides
Alfred Sandrock

Chief Executive Officer, Voyager Therapeutics (expected to hand over the CEO role in Q1 2027)

Verified
✓ voyagertherapeutics.com, 31 Oct 2026
Domain
voyagertherapeutics.com
Profile
LinkedIn not found

Executive Vice President, Research and Development at Biogen from October 2019 to December 20214

Influences
Michael Higgins

Chairman of the Board, Voyager Therapeutics

Verified
✓ voyagertherapeutics.com, 31 Oct 2026
Domain
voyagertherapeutics.com
Profile
LinkedIn not found

Interim President and CEO of Voyager from June 2021 to March 20224

Company details

CompanyVoyager Therapeutics, Inc.2
OwnershipPublic (Nasdaq: VYGR)1
TypeGene therapy developer (VY1706, a tau-targeted gene therapy for early Alzheimer's disease; FDA IND clearance 1 Jun 2026)3
Cash and runwayCash position of $149 million at end of Q2 2026; runway into 2028 (company statement, 6 Aug 2026)3
Address75 Hayden Avenue, Lexington, MA 024211
Main phone857.259.53401
Websitevoyagertherapeutics.com

Timeline

  1. Announces VY1706 and VY7523 poster presentations at CTAD 20263
  2. Board appoints Swartz President and expected CEO successor1
  3. Q2 2026 results: cash $149 million, runway into 20283
  4. FDA clears IND for VY17063
  5. CFO Nathan Jorgensen's resignation takes effect; Swartz becomes principal financial officer and treasurer, Quinlan principal accounting officer5
  6. CFO Jorgensen notifies the company of his resignation to pursue a new opportunity5

Sources

  1. ir.voyagertherapeutics.com (Form 8-K), 21 Oct 2026
  2. ir.voyagertherapeutics.com, 21 Oct 2026
  3. ir.voyagertherapeutics.com, checked 31 Oct 2026
  4. voyagertherapeutics.com, checked 31 Oct 2026
  5. ir.voyagertherapeutics.com (Form 8-K), 21 Apr 2026
08

Rapport Therapeutics (RAPP)

Boston MA ·

Positive Phase 2 bipolar mania data, then stock and convertible notes offerings closed; leadership page lists no commercial leader

Chief Commercial Officer

What happened

  • Positive topline results from the Phase 2 trial of RAP-219 in adults with acute bipolar mania, 20 Oct 2026; the trial met its primary endpoint1
  • Company plans an FDA meeting in Q1 2027 on registrational trial design; two Phase 3 trials in bipolar mania are expected to start in H2 20271
  • Phase 3 focal onset seizure trials FOCUS 1 and FOCUS 2 are already enrolling1
  • Underwritten common stock offering (net proceeds approximately $215.7 million) and $172.5 million convertible notes offering both closed 30 Oct 2026, with a concurrent private placement of about $30.0 million; proceeds are for RAP-219 clinical trials, other R&D and general corporate purposes23
  • Leadership page lists a CEO, CSO, COO, CFO, CMO, Chief Development Officer and Chief People Officer; it lists no commercial, business, regulatory or medical affairs leader (checked 31 Oct 2026)4
  • Greater China rights to RAP-219 are licensed to Tenacia Biotechnology (March 2026); Rapport keeps rights in all other territories5
  • Annual report states the company has exclusive global rights to commercialize its product candidates and will consider partnerships opportunistically6
  • In Aug 2026 the company stated it plans an End-of-Phase 2 meeting with the FDA to align on the design of a potential Phase 3 programme to support a New Drug Application for bipolar mania7

Seat in play

  • Chief Commercial Officer17524

Our read

RAP-219 now has two pivotal Phase 3 trials enrolling in focal onset seizures and, after positive Phase 2 bipolar mania data on 20 Oct 2026, an FDA meeting planned for Q1 2027 and two bipolar Phase 3 trials expected in H2 2027, with the company describing a potential Phase 3 programme to support a New Drug Application17. Rapport keeps RAP-219 rights everywhere outside Greater China, closed about $215.7 million of stock and $172.5 million of convertible notes on 30 Oct 2026, and its leadership page lists no commercial leader, so a commercial head to prepare a possible first launch across two indications may be among its next senior hires524. Companies preparing a first launch often put commercial leadership in place ahead of filing.

What could hold it back

  • Shown The CEO was previously Head of Commercial at Keryx and VP Marketing at Ironwood, and the COO's background covers marketing, sales and launch strategy, including the LINZESS launch; commercial planning may sit with them for now4.
  • Shown The October proceeds are stated for RAP-219 clinical trials, other R&D and general corporate purposes, not a commercial build, and the annual report says partnerships will be considered opportunistically26.
  • Open Whether the company will launch RAP-219 in the US itself or with a partner, whether commercial leaders already sit below the executive team, and when the focal onset seizure Phase 3 reads out (no date found).

About the decider: Abraham N. Ceesay

Abraham N. Ceesay is CEO of Rapport; before that he was President of Cerevel Therapeutics (May 2021 to Feb 2023), CEO of Tiburio Therapeutics, COO at scPharmaceuticals, Head of Commercial at Keryx and VP Marketing at Ironwood. The bipolar data and the October financing likely put the shape of the late-stage and pre-launch team for RAP-219 on his desk41.

Questions to ask Abraham N. Ceesay

  • With the FDA meeting planned for Q1 2027 and bipolar Phase 3 trials expected in H2 2027 alongside FOCUS 1 and FOCUS 2, how are you thinking about the leadership the company will need as RAP-219 moves toward a New Drug Application17?
  • Having led commercial work at Keryx and marketing at Ironwood, how do you see commercial preparation for RAP-219 across epilepsy and bipolar mania, and when should it begin4?
  • With Rapport keeping rights outside Greater China, how is the team weighing building its own US commercial organisation against partnering56?

Who to call

Decides
Abraham N. Ceesay

Chief Executive Officer, Rapport Therapeutics

Verified
✓ rapportrx.com, 31 Oct 2026
Domain
rapportrx.com
Profile
LinkedIn not found

President of Cerevel Therapeutics from May 2021 through February 20234

Runs the process
Kathy Wilkinson

Chief People Officer, Rapport Therapeutics

Verified
✓ rapportrx.com, 31 Oct 2026
Domain
rapportrx.com
Profile
LinkedIn

Joined Rapport after over a decade at bluebird bio and 2seventy bio, where she was Chief People Officer4

Career, from LinkedIn

  1. Chief People Officer, Rapport Therapeutics
  2. Chief People Officer, 2seventy bio
  3. Chief People Officer, bluebird bio
  4. Director, HR and Operations, Adnexus Therapeutics
  5. Sr HR Director, Codon Devices

Harvard University, BA, Sociology

Company details

CompanyRapport Therapeutics, Inc.1
OwnershipPublic (Nasdaq: RAPP)1
TypeClinical-stage biotech; lead programme RAP-219 in Phase 3 (focal onset seizures)1
Size84 full-time employees at 31 Dec 20256
Latest financingCommon stock offering (net proceeds approximately $215.7 million) and $172.5 million convertible notes, closed 30 Oct 2026; concurrent private placement of about $30.0 million2
Cash and runway$436.1 million in cash, cash equivalents and short-term investments at 30 Jun 2026, excluding restricted cash, expected to fund operations into the second half of 2029 (before the October offerings)1
Address99 High Street, Suite 2100, Boston, MA 021103
Main phone(857) 321-80203
Websiterapportrx.com8

Timeline

  1. Common stock and convertible notes offerings close2
  2. Positive Phase 2 topline results in bipolar mania1
  3. Company reports its Phase 3 focal onset seizure programme began in Q2 20269
  4. Tenacia Biotechnology licenses RAP-219 for Greater China; $20 million upfront5

Sources

  1. globenewswire.com, 20 Oct 2026
  2. readthrough.bio, 30 Oct 2026
  3. sec.gov, 8-K 28 Oct 2026
  4. rapportrx.com, checked 31 Oct 2026
  5. globenewswire.com, 9 Mar 2026
  6. sec.gov, 10-K FY2025, 10 Mar 2026
  7. sec.gov, 8-K Ex 99.1, 5 Aug 2026
  8. rapportrx.com, checked 31 Oct 2026
  9. investors.rapportrx.com, 5 Aug 2026
09

TriGemX Bio (TGEM (proposed, Nasdaq))

New York NY ·

SPAC merger with TCGX Acquisition Corp. announced with $160M PIPE, about $246M expected gross proceeds; Phase 3 migraine programme; no commercial or regulatory leader on leadership page

Chief Commercial OfficerIndependent Board DirectorGeneral Counsel

What happened

  • TriGemX Bio and TCGX Acquisition Corp. (Nasdaq: TCGX) announced a definitive business combination agreement on 19 Oct 2026; the combined company will be TriGemX Bio, Inc. and is expected to trade on Nasdaq as TGEM1
  • Expected gross proceeds are about $246 million: about $86 million in TCGX's trust account (assuming no redemptions) and a concurrent $160 million PIPE at $10.00 per share from investors including TCGX, Viking Global Investors, ADAR1 Capital Management, BVF Partners, Samsara BioCapital and Vianti Capital1
  • The proceeds are to fund completion of the Phase 3 trials and an NDA submission for acute migraine, a migraine prevention trial, and key commercial readiness activities for a potential U.S. launch1
  • CEO Jeff Goater said the proceeds will fully fund Phase 3 development of elismetrep and key commercial readiness activities as the company prepares for a potential U.S. launch1
  • Closing is expected in the first quarter of 2027, subject to shareholder approvals and customary conditions; results from the first Phase 3 trial are anticipated in mid-20271
  • Existing TriGemX shareholders roll 100% of their equity; post-transaction equity value about $600 million assuming no redemptions1
  • Leadership page (checked 31 Oct 2026) lists CEO, President & Chief Medical Officer, CFO, VP Head of HR and FP&A, and VP Corporate Controller; it lists no commercial, regulatory, clinical operations, CMC, legal, investor relations or medical affairs leader2
  • Two pivotal Phase 3 studies and a long-term safety study of elismetrep are underway3
  • After closing, the New TriGemX board will initially have seven directors: six TriGemX designees, at least three of them independent under Nasdaq rules, and one TCGX designee, with a majority independent4
  • TriGemX's obligation to close is conditional on Available Closing Cash of at least $150,000,000; either party may terminate, subject to limited exceptions, if the deal has not closed by 30 Jun 20274
  • On 1 Oct 2026 the company relaunched as TriGemX with Jeff Goater appointed CEO and Aninda Katragadda CFO; Goater joined from The Column Group, where he continues as a Venture Partner, and previously was CEO of Surface Oncology and CFO of Voyager Therapeutics5
  • Cariad Chester, Managing Partner at TCGX, joined the TriGemX board as part of the $94M financing5
  • Doug Pagán, CFO of Kailera Therapeutics, was appointed to the TriGemX board on 5 Oct 20266

Seat in play

  • Chief Commercial Officer12
  • Independent Board Director412
  • General Counsel12

Our read

TriGemX says the about $246 million from its planned Nasdaq listing, expected to close in the first quarter of 2027, is to fund completion of Phase 3, an NDA submission for acute migraine and commercial readiness for a potential U.S. launch, yet its leadership page lists no commercial or legal leader12. The merger agreement sets a seven-person board after closing with a majority independent under Nasdaq rules, so board composition is likely to be worked on ahead of the listing4. With first Phase 3 results expected in mid-2027, a company preparing a first U.S. launch usually puts commercial leadership in place well ahead of approval, so these seats may form before the readout rather than after it1.

What could hold it back

  • Shown The closing is subject to shareholder approval and at least $150 million of available closing cash, and proceeds could be lower with redemptions; the agreement can be ended if the deal has not closed by 30 Jun 20274.
  • Shown The board already lists Doug Pagán, appointed on 5 Oct 2026, so the post-closing board may be drawn largely from current directors26.
  • Open Whether commercial hiring waits for the mid-2027 Phase 3 results, and whether The Column Group or TCGX will place executives from their own networks.

About the decider: Jeff Goater

Jeff Goater has been CEO since the company's relaunch as TriGemX on 1 Oct 2026, joining from The Column Group (still a Venture Partner) after serving as CEO of Surface Oncology and CFO of Voyager Therapeutics; his LinkedIn profile shows him a Partner at The Column Group from Jan 2024 to Sep 202657.

Questions to ask Jeff Goater

  • How are you thinking about the leadership team TriGemX needs in place by the time it lists on Nasdaq1?
  • The proceeds are earmarked for commercial readiness ahead of a potential U.S. launch: how do you see the commercial organisation taking shape around the mid-2027 Phase 3 results1?
  • With a seven-person, majority-independent board planned after closing, what experience is the board looking to add as the company becomes public4?

Who to call

Decides
Jeff Goater

Chief Executive Officer, TriGemX Bio

Verified
✓ trigemxbio.com, 31 Oct 2026
Domain
trigemxbio.com
Profile
LinkedIn

Career, from LinkedIn

  1. Board Member, GreatPoint Therapeutics
  2. Venture Partner, The Column Group
  3. Chief Executive Officer, TriGemX Bio
  4. Board Member, TriGemX Bio
  5. Board Member, Tortugas Neuroscience
  6. Board Member, Kenai Therapeutics
  7. Chair, AviadoBio
  8. Partner, The Column Group
  9. Venture Partner, The Column Group
  10. Board Member, Judo Bio
  11. Executive Chair, Judo Bio

University of Rochester - Simon Business School, MBA; University of Rochester School of Medicine and Dentistry, MS, Microbiology / Immunology; University of Rochester School of Medicine and Dentistry, MS, Pathology

Runs the process
Maury Spadoto

Vice President - Head of HR and FP&A, TriGemX Bio

Verified
✓ trigemxbio.com, 31 Oct 2026
Domain
trigemxbio.com
Profile
LinkedIn

Career, from LinkedIn

  1. Vice President - Human Resources and Financial Planning & Analysis, TriGemX Bio
  2. Vice President - FP&A and HR, Kallyope
  3. Senior Director - Head of Financial Planning & Analysis, Kallyope
  4. Controller, Curinos
  5. Global Financial Controller, Ichnos Sciences
  6. Vice President - Finance, Build America Mutual

Rutgers University, Bachelor of Science - BS, Accounting

Influences
Cariad Chester

Board Director, TriGemX Bio; Managing Partner, TCGX

Verified
✓ trigemxbio.com, 1 Oct 2026
Domain
not found
Profile
LinkedIn

Career, from LinkedIn

  1. Managing Partner, TCGX
  2. Managing Director, Aquilo Capital
  3. Immunotherapy Research, Stanford University School of Medicine

Swarthmore College, Double Major: Neuroscience and Comparative Religious Studies

Company details

CompanyTriGemX Bio, Inc. (formerly Kallyope)8
OwnershipPrivate, venture-backed; to become Nasdaq-listed (TGEM) on closing of the TCGX merger, expected Q1 20271
InvestorsThe Column Group, TCGX and Viking Global Investors co-led the $94M round8
TypeClinical-stage biotech (Phase 3, elismetrep, oral TRPM8 blocker for acute migraine)3
Latest financing$94M round co-led by The Column Group, TCGX and Viking Global Investors (1 Oct 2026)8
Cash and runwayCompany states the anticipated transaction proceeds would position it to fully fund Phase 3 development of elismetrep; no runway date stated1
AddressNew York, NY 100162
Websitetrigemxbio.com

Timeline

  1. Business combination agreement with TCGX Acquisition Corp.; $160M PIPE9
  2. Announced $94M financing co-led by The Column Group, TCGX and Viking Global Investors8
  3. New data on elismetrep presented at the American Headache Society annual meeting (release issued under the Kallyope name)9
  4. Positive results from Phase 2b study of elismetrep for acute migraine (release issued under the Kallyope name)9

Sources

  1. trigemxbio.com, 19 Oct 2026
  2. trigemxbio.com, checked 31 Oct 2026
  3. trigemxbio.com, checked 31 Oct 2026
  4. sec.gov, 8-K report dated 18 Oct 2026
  5. trigemxbio.com, 1 Oct 2026
  6. trigemxbio.com, 5 Oct 2026
  7. linkedin.com
  8. finsmes.com, 1 Oct 2026
  9. trigemxbio.com, checked 31 Oct 2026

Senior seats covered by an interim or acting leader. The permanent choice is still ahead; an interim can run a year or more, and may be a candidate.

#CompanyHeadlineSeat in playDecides
10Cardiff Oncology, Inc.
San Diego CA
Chief Medical Officer departed; interim CMO on a consulting agreement to 22 Apr 2027; Phase 3 planned Q1 2027Chief Medical Officer: OpenMani Mohindru, PhD
President and Chief Executive Officer, Cardiff Oncology
11Enanta Pharmaceuticals
Watertown MA
CEO Jay Luly to retire by 1 Feb 2027; board search under way, internal and external candidates, no successor named; new COO role createdPresident and Chief Executive Officer: Open from 2027-02-01 · Chief Financial Officer: Open · VP Regulatory Affairs: ProbableBruce L. A. Carter
Chairman of the Board, Enanta Pharmaceuticals

Open roles

10

Cardiff Oncology, Inc. (CRDF)

San Diego CA ·

Chief Medical Officer departed; interim CMO on a consulting agreement to 22 Apr 2027; Phase 3 planned Q1 2027

Chief Medical Officer: open

What happened

  • Roger Sidhu, MD, separated as Chief Medical Officer on 22 Oct 2026 in a mutually agreed transition (8-K filed 27 Oct 2026)1
  • Leila Alland, MD, named interim Chief Medical Officer, announced 27 Oct 2026; she succeeds Dr. Sidhu2
  • Dr. Alland serves under an amended and restated consulting agreement from 23 Oct 2026 until the earlier of 22 Apr 2027 or completion of services, extendable by mutual agreement; $35,000 a month for up to 50% of her professional time1
  • Neither the release nor the 8-K names a permanent successor, a search or a search firm, and neither states that Dr. Alland is a candidate for the permanent role21
  • The company plans to start its registrational Phase 3 study in first-line RAS-mutated metastatic colorectal cancer in Q1 20272
  • Phase 3 start is subject to securing additional financing, per the Q2 2026 results release (11 Aug 2026)3
  • Management page lists President & CEO, COO, CFO, Chief Accounting Officer and CSO plus the interim CMO; no head of people, regulatory, commercial or VP clinical development is listed (checked 31 Oct 2026)4
  • The registrational Phase 3 (CRDF-005) is designed as a global randomized controlled trial expected to enrol about 640 patients across sites in the US, Europe and other regions5
  • On 14 Sep 2026 Cardiff and Nerviano entered a settlement resolving the litigation and amended the onvansertib licence; the amendment gives Nerviano a board observer seat and a Scientific Advisory Board seat6
  • At a September 2026 investor conference, management said it is exploring possible regional partnerships and other collaborations to fund the Phase 37

Seat in play

  • Chief Medical Officer: Open (held on an interim basis by Leila Alland, MD, under a consulting agreement to 22 Apr 2027; no search or firm named)1

Our read

Cardiff's CMO separated on 22 Oct 2026 and the seat is held by an interim on a part-time consulting agreement that runs to 22 Apr 2027, with no successor, search or candidate named, so the choice of a permanent CMO appears to be still ahead12. The company plans to start a registrational, global Phase 3 of onvansertib in first-line RAS-mutated metastatic colorectal cancer in Q1 2027, enrolling about 640 patients across the US, Europe and other regions, which suggests the permanent holder may need late-stage oncology trial and regulatory experience25. The licence dispute with Nerviano over onvansertib was settled on 14 Sep 2026, and the CEO and CFO seats were filled in April 202668.

What could hold it back

  • Shown The Phase 3 start is subject to securing additional financing; cash of $34.5 million at 30 Jun 2026 is stated to last into Q3 2027, and the 10-Q states substantial doubt about the company continuing as a going concern35.
  • Shown The COO, Ajay Aggarwal, was previously SVP and Head of Clinical Development at Aclaris and CMO of CereXis, and could cover part of the clinical work; the interim's agreement can also be extended by mutual agreement41.
  • Open Whether Dr. Alland is a candidate for the permanent role, and whether a search or firm is already engaged.

What filling it could set off (our read)

Dr. Alland is an outside consultant, so confirming her may leave no seat behind at Cardiff. An outside appointee may leave a seat at their previous employer, unknown until named, and a new CMO preparing a roughly 640-patient global Phase 3 may often add clinical development leadership (the management page lists no VP Clinical Development)154.

About the decider: Mani Mohindru, PhD

Mani Mohindru, PhD, has been President and CEO of Cardiff Oncology since late March 2026 after serving as interim CEO from January 2026, and has been a director since 2021; she was earlier CEO of Novasenta and CereXis and CFO and Chief Strategy Officer of Cara Therapeutics. With the CMO separated and an interim in place to April 2027, she is likely to decide on a permanent CMO while preparing a Q1 2027 Phase 3 start that depends on new financing43.

Questions to ask Mani Mohindru, PhD

  • With the registrational Phase 3 in first-line RAS-mutated colorectal cancer planned for Q1 2027, what profile are you looking for in the medical leader who takes it through enrolment and readout2?
  • Having built a new executive team this year, with a CFO and a COO who has led clinical development, how do you see the medical and clinical roles dividing as the trial runs across the US and Europe845?
  • Dr. Alland's agreement runs to April 2027; how are you thinking about the timing of a permanent CMO relative to the Phase 3 financing and start1?

Who to call

Decides
Mani Mohindru, PhD

President and Chief Executive Officer, Cardiff Oncology

Verified
✓ cardiffoncology.com, 31 Oct 2026
Domain
cardiffoncology.com
Profile
LinkedIn

Interim CEO from January 2026, President and CEO from late March 2026, director since 2021; previously CEO of Novasenta and CereXis, and CFO and Chief Strategy Officer of Cara Therapeutics4

Influences
Ajay Aggarwal, MD, MBA

Chief Operating Officer, Cardiff Oncology

Verified
✓ cardiffoncology.com, 31 Oct 2026
Domain
cardiffoncology.com
Profile
LinkedIn not found

Joined April 2026; previously SVP and Head of Clinical Development at Aclaris Therapeutics and Chief Medical Officer of CereXis4

Company details

CompanyCardiff Oncology, Inc.2
OwnershipPublic (Nasdaq: CRDF)2
TypeClinical-stage biotech; lead onvansertib in a Phase 2 trial, registrational Phase 3 planned Q1 20272
Latest financingRegistered direct offering of common stock and warrants, about $10.1 million gross proceeds, completed 14 Jul 20265
Cash and runway$34.5 million in cash, cash equivalents and short-term investments at 30 Jun 2026 (before the July offering); company states cash is sufficient to fund operations into the third quarter of 2027; 10-Q states substantial doubt about ability to continue as a going concern5
Address11055 Flintkote Ave., San Diego, CA 921214
Main phone858-952-75704
Websitecardiffoncology.com9

Timeline

  1. Interim CMO Leila Alland announced; CMO Roger Sidhu separated 22 Oct1
  2. Settlement with licensor Nerviano Medical Sciences amending the 2017 licence for onvansertib, resolving litigation10
  3. Q2 2026 results: $34.5 million cash and investments at 30 Jun, runway into Q3 2027; Phase 3 start Q1 2027 subject to financing3
  4. About $10.1 million registered direct offering completed5
  5. Cardiff sued licensor Nerviano Medical Sciences, which had alleged material breach in Feb 2026 and purported to terminate the licence3
  6. Mani Mohindru named President and CEO; Josh Muntner appointed CFO (effective 6 Apr) and Ajay Aggarwal COO (effective 27 Apr)8
  7. CEO Mark Erlander and CFO James Levine stepped down as part of a strategic leadership review; Mohindru named interim CEO; Brigitte Lindsay promoted to Chief Accounting Officer; search for permanent CEO and CFO started11

Sources

  1. sec.gov 8-K, 27 Oct 2026
  2. globenewswire.com, 27 Oct 2026
  3. sec.gov, 11 Aug 2026
  4. cardiffoncology.com, checked 31 Oct 2026
  5. sec.gov 10-Q, 11 Aug 2026
  6. investors.cardiffoncology.com 8-K, 14 Sep 2026
  7. investing.com, 14 Sep 2026
  8. sec.gov, 9 Apr 2026
  9. cardiffoncology.com, checked 31 Oct 2026
  10. tickeron.com, 28 Oct 2026
  11. sec.gov, 27 Jan 2026

Open roles, search begun

11

Enanta Pharmaceuticals (ENTA)

Watertown MA ·

CEO Jay Luly to retire by 1 Feb 2027; board search under way, internal and external candidates, no successor named; new COO role created

President and Chief Executive Officer: open from 2027-02-01Chief Financial Officer: openVP Regulatory Affairs: probable

What happened

  • Enanta announced on 28 Oct 2026 that Jay R. Luly, Ph.D., age 70, will retire as President and Chief Executive Officer by 1 Feb 2027 after 23 years, and will serve as Strategic Advisor for the remainder of 20271
  • The Board of Directors has initiated a search for Dr. Luly's successor, considering both internal and external candidates; no successor, interim or search firm is named in the release1
  • Tara L. Kieffer, Ph.D., previously Chief Product Strategy Officer, was appointed to the newly created role of Chief Operating Officer; the release does not say she is a candidate for CEO1
  • Harry R. Trout III, Vice President, Finance, was designated interim principal financial officer by the board on 26 Aug 2025, in place of the Chief Financial and Administrative Officer; he signed the 10-Q of 12 Aug 2026 as Principal Financial Officer. No permanent Chief Financial Officer is named on a page opened23
  • The management team page lists the CEO, COO, Chief Legal Officer, Chief Business Officer, Chief Scientific Officer and Chief Medical Officer; it lists no Chief Financial Officer, head of people, commercial or regulatory leader (checked 31 Oct 2026)4
  • Enanta decided to lay off 37 employees, right-sizing across all departments, according to Fierce Biotech (29 Sep 2026)5
  • Lead programme zelicapavir (RSV): Enanta announced on 26 Oct 2026 that the first patient was dosed in the global Phase 2b/3 RESOLVE trial; topline Phase 2b data expected in 20276
  • Cash, cash equivalents and marketable securities were $211.5 million at 30 Jun 2026; the company states its funds, with retained HCV royalties, last into fiscal 20293
  • The Phase 2b portion of RESOLVE will include at least 200 patients and is designed to confirm the treatment effect size; the Phase 3 portion is expected to enroll about 660 patients6
  • The CEO retirement release lists among its risk factors Enanta's lack of clinical development experience and its ability to partner its RSV or other programs1

Seat in play

  • President and Chief Executive Officer: Open from 2027-02-01 (Dr. Luly retires "by February 1, 2027" (date may be earlier); board search under way, internal and external; no successor named)1
  • Chief Financial Officer: Open (duties held by Harry R. Trout III, Vice President, Finance, designated interim principal financial officer on 26 Aug 2025; no permanent CFO named on a page opened)23
  • VP Regulatory Affairs: Probable (our read)64

Our read

The board has begun a search for a successor to CEO Jay Luly, who plans to retire by 1 Feb 2027, and is considering external as well as internal candidates, so the choice of a permanent leader is likely still ahead1. The finance seat has been covered on an interim basis by VP Finance Harry Trout since Aug 2025 and the management team page lists no CFO234. The next CEO would take over as the lead RSV programme zelicapavir enters a Phase 2b/3 trial, with Phase 2b data expected in 2027 and funding stated to last into fiscal 2029, which may shape the profile the board looks for63.

What could hold it back

  • Shown The board is considering internal candidates, and Tara Kieffer was named to the newly created COO role on the same day, a natural successor seat for CEO1.
  • Open Whether a search firm is already engaged for the CEO search the board began on 28 Oct 2026.
  • Shown The Phase 3 portion of RESOLVE follows Phase 2b data expected in 2027, and the company decided to lay off 37 employees, as reported in Sep 2026, so a regulatory hire may wait for the data or be covered by the existing clinical team65.

What filling it could set off (our read)

If the board appoints from within, the seat that person holds now, such as Chief Operating Officer (Tara Kieffer) or Chief Business Officer (Brendan Luu), may open. A new CEO often reshapes the seats reporting to them in the first year, and may look to fill the CFO seat that a VP Finance has covered on an interim basis since Aug 2025142.

About the decider: Bruce L. A. Carter

Bruce Carter has chaired Enanta's board since Dec 2015 (director since Nov 2013) and was President and CEO of ZymoGenetics from 1998 to 2009 and Chief Scientific Officer of Novo Nordisk from 1994 to 1999. The board he chairs has opened the search for Jay Luly's successor, with internal and external candidates, ahead of a retirement dated by 1 Feb 202771.

Questions to ask Bruce L. A. Carter

  • Having led ZymoGenetics as CEO for over a decade, how is the board thinking about the experience Enanta's next chief executive will need as zelicapavir moves through RESOLVE toward Phase 2b data in 202776?
  • With Tara Kieffer now in the newly created COO role, how does the board see the senior team taking shape around the next CEO1?
  • How is the board thinking about finance leadership alongside the CEO transition34?

Who to call

Decides
Bruce L. A. Carter

Chairman of the Board, Enanta Pharmaceuticals

Verified
✓ businesswire.com, 28 Oct 2026
Domain
enanta.com
Profile
LinkedIn not found

Board member since Nov 2013 and Chairman since Dec 2015; former President and CEO of ZymoGenetics (1998 to 2009) and Chief Scientific Officer of Novo Nordisk (1994 to 1999)7

Influences
Tara L. Kieffer

Chief Operating Officer, Enanta Pharmaceuticals

Verified
✓ enanta.com, 31 Oct 2026
Domain
enanta.com
Profile
LinkedIn

Joined Enanta in Dec 2020, most recently Chief Product Strategy Officer; previously Vice President of External Innovation and Business Development and Vice President of Integrated Program Management at Vertex Pharmaceuticals4

Career, from LinkedIn

  1. Chief Operating Officer, Enanta Pharmaceuticals
  2. Chief Product Strategy Officer, Enanta Pharmaceuticals
  3. SVP, New Product Strategy and Development, Enanta Pharmaceuticals
  4. VP, External Innovation, Business Development, Vertex Pharmaceuticals
  5. VP, Integrated Program Management, Vertex Pharmaceuticals

The Johns Hopkins University School of Medicine, Doctor of Philosophy - PhD, Immunology; Colgate University, Bachelor of Arts - BA, Molecular Biology; Damascus High School

Company details

CompanyEnanta Pharmaceuticals, Inc.1
OwnershipPublic, Nasdaq: ENTA1
TypeClinical-stage biotech (lead programme zelicapavir, RSV, in Phase 2b/3); receives royalties on AbbVie's MAVYRET/MAVIRET6
Size120 full-time employees at 30 Sep 2025 (annual report, as reported by Fierce Biotech); layoff of 37 reported 29 Sep 20265
Latest financingUpsized public offering of common stock closed 2 Oct 2025: 7,475,000 shares at $10.00, gross proceeds $74.75 million8
Cash and runway$211.5 million in cash, cash equivalents and marketable securities at 30 Jun 2026; funds, with retained HCV royalties, expected to last into fiscal 20293
Address4 Kingsbury Avenue, Watertown, MA 024724
Main phone(617) 607-08004
Websiteenanta.com

Timeline

  1. Announces CEO Jay Luly's planned retirement by 1 Feb 2027, a board search for his successor, and Tara Kieffer as COO in a newly created role1
  2. First patient dosed in the Phase 2b/3 RESOLVE trial of zelicapavir in high-risk adults with RSV6
  3. Reported layoff of 37 employees across all departments5
  4. Fiscal Q3 10-Q: $211.5 million cash and securities, runway into fiscal 2029; Harry Trout signs as Principal Financial Officer3
  5. Closes upsized public offering, $74.75 million gross proceeds8
  6. Board designates VP Finance Harry R. Trout III interim principal financial officer in place of the Chief Financial and Administrative Officer2

Sources

  1. businesswire.com, 28 Oct 2026
  2. sec.gov, 8-K, 27 Aug 2025
  3. sec.gov, 10-Q, 12 Aug 2026
  4. enanta.com, checked 31 Oct 2026
  5. fiercebiotech.com, 29 Sep 2026
  6. businesswire.com, 26 Oct 2026
  7. enanta.com, checked 31 Oct 2026
  8. businesswire.com, 2 Oct 2025